Utama › Penyakit Hati Steatotik › North Carolina
Kajian klinikal Penyakit Hati Steatotik di North Carolina
13 kajian untuk Penyakit Hati Steatotik sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 27 Jul 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Jul 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 42 · Wanita · Dikemas kini 13 Apr 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Apr 2026 · NCT07495332Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.